• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
February 05, 2018

Tim McCarthy, Chairman of Immupharma discusses the completion of Lupuzor™ pivotal phase III study and initiation of follow up study.

Read More
January 15, 2018

Small Company Share Watch – Jan 2018…

Read More
October 04, 2017

Q&A with Tim McCarthy Non-Executive Chairman at ImmuPharma PLC (LON:IMM)

Read More
September 28, 2017

On the right track – Sept 2017

Read More
May 30, 2017

Business insights from Small Cap Leaders – May 2017

Read More
April 13, 2017

Why Lupus Treatment is a potential game-changer – April 2017

Read More
April 10, 2017

All Street Cap – April 2017

Read More
August 25, 2016

Healthcare Heroes – Shares magazine, August 2016

Read More
July 07, 2016

Northland Capital Partners ImmuPharma Initiation VA – July 2016

Read More
July 01, 2016

AIM Journal – July 2016

Read More
June 08, 2016

Lupus news today – June 2016

Read More
March 08, 2016

Growth Company Investor – March 2016

Read More
  • 1
  • 2
  • 3
  • 4
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved